Esta web utiliza cookies técnicas, de personalización y de análisis, propias y de terceros, para anónimamente facilitarle la navegación y analizar estadísticas del uso de la web. Obtener más información
Resultados de búsqueda
-
Crown Cork & Seal Co., Inc. (Spanish Version)
Hamermesh, Richard G.; Gordon, Karen; Reed, John P.Caso HBS-302S28Dirección estratégicaDescribe las tendencias técnicas, económicas y competitivas en la industria del envase metálico. La estrategia de Crown Cork and Seal se describe a continuación en relación con estas tendencias. Se centra en dos amenazas inmediatas a la estrategia de la corona: el futuro de las latas de aerosol, teniendo en cuenta el problema del ozono; y el impacto de la prohibición de los recipientes no retornables.Desde 8,20 €
-
Reinventing Brainlab
Herzlinger, Regina E.; Dessain, Vincent; Misztal, KarolCaso HBS-313069-EDirección estratégicaThe management of Germany's Brainlab AG, a leading provider of software-driven oncology and surgery solutions, needs to evaluate strategic options for proceeding without an exclusive hardware partner in its most profitable business segment.Desde 8,20 €
-
Sanofi Pasteur: The Dengue Vaccine Dilemma
Rangan, V. Kasturi; Bloom, David E.; Dessain, Vincent; Billaud, EmilieCaso HBS-514074-EIn 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a good balanced immune answer, it had a proof of efficacy of only 30%, far below the 70% mark the company had targeted. Guillaume Leroy, vice president of the Dengue Company at Sanofi Pa...Desde 8,20 €
-
General Electric, 1984 (Spanish Version)
Aguilar, Francis J.; Hamermesh, Richard G.; Brainard, Caroline E.Caso HBS-302S36Conocimiento y comunicaciónDescribe los primeros cuatro años de permanencia de Jack Welch como CEO de las ofertas de General Electric Co. con las formas Welch ha tratado de actividades de estrategia y planificación del cambio de GE y sus intentos de hacer la empresa más empresarial.Desde 8,20 €
-
Bloodbuy
Hamermesh, Richard G.; Norris, MichaelCaso HBS-815114-EIniciativa emprendedoraIn 2015, Chris Godfrey, founder and CEO of Bloodbuy has to consider the best path to growth for his young company that is attempting to disrupt the blood donation industry.Desde 8,20 €
-
Amylin Pharmaceuticals B
Hamermesh, Richard G.; Knoop, Carin-IsabelCaso HBS-813091-EIniciativa emprendedoraSupplement for case 809011Desde 8,20 €
-
Novasys Medical
Hamermesh, Richard G.; Barley, LaurenCaso HBS-810027-EIniciativa emprendedoraNovasys has developed a new medical device and procedure for the treatment of female stress urinary incontinence that is cheaper and can be performed in doctors' offices. In spite of FDA approval, the American Medical Association has been unwilling to approve the product for reimbursement. The case deals with the company's struggle to obtain a reimbursement code.Desde 8,20 €
-
Impact Investing for Cancer
Hamermesh, Richard G.; Preble, MatthewCaso HBS-818068-EDirección estratégicaDesde 8,20 €
-
Medalogix
Hamermesh, Richard G.; Preble, MatthewCaso HBS-815116-EIniciativa emprendedoraThis case examines an exciting new approach to health care that will help care providers identify when hospice services are the appropriate type of care for patients. The company, Medalogix, already has a product on the market that uses a proprietery algorithm to consider dozens of factors and determine when a patient qualifies for a hospice care eligability review. The product has started to gain traction, and the case explores how Medalogix can...Desde 8,20 €
-
Gene Patents (A)
Hamermesh, Richard G.; Kiron, David; Andrews, PhillipCaso HBS-811089-EIniciativa emprendedoraIn March 2010, U.S. District Court Judge Robert Sweet overturned 30 years of legal precedent and ruled that unaltered human genes could not be patented. This case reviews patent law and how it relates to our increasing knowledge of the Human Genome. The case issues deal with the potential implications of Judge Sweet's decision for biotechnology entrepreneurs and investors.Desde 8,20 €